Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer

被引:39
|
作者
Adashek, Jacob J. [1 ]
Jain, Rohit K. [2 ]
Zhang, Jingsong [2 ]
机构
[1] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Internal Med, Tampa, FL 33612 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USA
关键词
PARP inhibitors; DNA damage repair deficiency; prostate cancer; targeted therapy; DNA-REPAIR; POLY(ADP-RIBOSE) POLYMERASE; MAINTENANCE THERAPY; OVARIAN-CANCER; MUTANT-CELLS; OLAPARIB; NIRAPARIB; DEFECTS; TUMORS; BRCA2;
D O I
10.3390/cells8080860
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The approval of upfront abiraterone for castration-sensitive prostate cancer and the approval of enzalutamide and apalutamide for non-metastatic castration-resistant prostate cancer have led to early utilization of potent androgen receptor (AR) signaling inhibitors in treating advanced prostate cancer. There is an unmet need to develop novel therapies beyond targeting AR signaling for metastatic castration-resistant prostate cancer (mCRPC). Poly (ADP-ribose) polymerase inhibitors (PARPi) belong to a class of targeted agents being developed for the treatment of homologous recombination repair (HRR) deficient tumors. Olaparib, rucaparib, niraparib, veliparib, and talazoparib were evaluated in early phase trials as a monotherapy for HRR-deficient mCRPC. Among them, olaparib and rucaparib have breakthrough designations for BRCA1/2-mutated mCRPC. Phase II studies also reported clinical activity of the PARPi and abiraterone combination and the PARPi checkpoint inhibitor combination in HRR-intact mCRPC. Ongoing phase III trials are testing these combinations as frontline or later line treatments for mCRPC. This review summarizes the critical clinical data as well as ongoing clinical trials for developing PARPi in treating mCRPC.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Olaparib in Metastatic Castration-Resistant Prostate Cancer
    Biswas, Bivas
    Ganguly, Sandip
    Ghosh, Joydeep
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1174 - 1175
  • [22] Biomarkers in Metastatic Castration-resistant Prostate Cancer
    Miller, K.
    AKTUELLE UROLOGIE, 2015, 46 (01) : 66 - 70
  • [23] Olaparib in metastatic castration-resistant Prostate Cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [24] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    de Bono, J.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Sandhu, S.
    Chi, K. N.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Mehra, N.
    Goessl, C.
    Kang, J.
    Burgents, J.
    Wu, W.
    Kohlmann, A.
    Adelman, C. A.
    Hussain, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22): : 2091 - 2102
  • [25] Advances in metastatic castration-resistant prostate cancer
    Kentepozidis, Nikolaos
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S108 - S108
  • [26] Rucaparib in castration-resistant, metastatic prostate cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2024, 55 (02) : 96 - 98
  • [27] Management of Metastatic Castration-Resistant Prostate Cancer
    Srinivas, Sandy
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 614 - 616
  • [28] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    Heidegger, Isabel
    Pircher, Andreas
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 890 - 891
  • [29] Treatment of metastatic, castration-resistant prostate cancer
    von Amsberg, G.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 673 - 679
  • [30] Cabazitaxel in metastatic castration-resistant prostate cancer
    Yap, Timothy A.
    Pezaro, Carmel J.
    de Bono, Johann S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (09) : 1129 - 1136